Abstract
This study compared the results of allogeneic peripheral blood stem cell transplantation (PBSCT) from unrelated and related donors, and involved 235 consecutive patients from ten centers between Jan 2004 and Dec 2008. Among these patients, 160 (68.1%) received a human leukocyte antigen-matched related PBSCT and 75 (31.9%), a matched unrelated PBSCT. The cumulative incidence of acute graft-versus-host disease (GVHD) was 43.9% for the related PBSCT and 59.3% for the unrelated PBSCT. Although the cumulative incidence of chronic GVHD was no different between the related (54.2%) and unrelated (64.9%) PBSCT, the cumulative incidence of extensive chronic GVHD was higher among the unrelated PBSCT (34.9%) than among the related PBSCT (17.0%). The overall survival rate at 4 years was 58.2% versus 49.1%, and the cumulative incidence of relapse was 28.4% versus 25.0% for the related and unrelated PBSCT, respectively. Among the factors examined, unrelated PBSCT, the CD34-positive cell count, and cytomegalovirus infection were all related with a higher incidence of extensive chronic GVHD. However, in a multivariate analysis, only unrelated PBSCT was identified as a risk factor for the development of extensive chronic GVHD (hazard ratio = 2.012; P value, 0.048). In conclusion, the survival and relapse incidence were not significantly different between the related and unrelated PBSCT.
Similar content being viewed by others
References
de Lima M, Champlin R (2001) Unrelated donor hematopoietic transplantation. Rev Clin Exp Hematol 5:100–134
Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D, Petersdorf E, Nelson G, McGlave P (2002) Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99:1971–1977
Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, Chehata S, Esperou H, Vernant JP, Michallet M, Buzyn A, Gratecos N, Cahn JY, Bourhis JH, Chir Z, Raffoux C, Socie G, Golmard JL, Jouet JP (2006) Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 24:5695–5702
Hurley CK, Wagner JE, Setterholm MI, Confer DL (2006) Advances in HLA: practical implications for selecting adult donors and cord blood units. Biol Blood Marrow Transplant 12:28–33
Russell JA, Brown C, Bowen T, Luider J, Ruether JD, Stewart D, Chaudhry A, Booth K, Jorgenson K, Coppes MJ, Turner AR, Larratt L, Desai S, Poon MC, Klassen J (1996) Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 17:703–708
Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H (1996) Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 88:2775–2779
Korbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H, Anderlini P, van Besien K, Andreeff M, Przepiorka D, Deisseroth AB, Champlin RE (1995) Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 86:2842–2848
Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW, Appelbaum FR, Bryant E, Chauncey TR, Sale G, Sanders JE, Storb R, Sullivan KM, Anasetti C (1997) Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 89:4226–4235
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825–828
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204–217
Mattsson J (2008) Recent progress in allogeneic stem cell transplantation. Curr Opin Mol Ther 10:343–349
Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J, Durrant S, Schwarer A, Bardy P, Herrmann R, Dodds A (2007) Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 13:601–607
Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R, Martin PJ, Flowers ME, Storek J, Georges G, Storb R, Torok-Storb B (2001) CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 98:3221–3227
Sohn SK, Kim JG, Kim DH, Lee NY, Suh JS, Lee KB (2003) Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transplant 31:967–972
Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD, Loberiza FR, Gratwohl A, Champlin RE (2006) Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 108:4288–4290
Zuckerman T, Rowe JM (2007) Alternative donor transplantation in acute myeloid leukemia: which source and when? Curr Opin Hematol 14:152–161
Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ, Chung JS, Cho GJ, Yang DH, Lee JJ, Kim YK, Kim HJ (2007) New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant 40:541–547
Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA, Barrett AJ, Cahn JY, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringden O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MM (2000) T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95:3996–4003
Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96:2062–2068
Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373:1550–1561
Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI, Storb R, Appelbaum FR, Forman SJ, Blume KG, Martin PJ (2002) Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100:415–419
Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O (2005) Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 105:548–551
Lonnqvist B, Aschan J, Ljungman P, Ringden O (1990) Long-term cyclosporin therapy may decrease the risk of chronic graft-versus-host disease. Br J Haematol 74:547–548
Young NS, Scheinberg P, Calado RT (2008) Aplastic anemia. Curr Opin Hematol 15:162–168
Perez-Simon JA, Sanchez-Abarca I, Diez-Campelo M, Caballero D, San Miguel J (2006) Chronic graft-versus-host disease: pathogenesis and clinical management. Drugs 66:1041–1057
Brunet S, Urbano-Ispizua A, Ojeda E, Ruiz D, Moraleda JM, Diaz MA, Caballero D, Bargay J, de la Rubia J, Solano C, Zuazu J, Diez JL, de la Serna J, Espigado I, Alegre A, Torres JP, Jurado M, Fernandez M, Vivancos P, Carreras E, Hernandez F, Maldonado J, Sierra J, Rozman C (2001) Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. Br J Haematol 114:544–550
Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S, Schwarer AP, Hughes T, Herrmann R, Gibson J, Arthur C, Matthews J (1999) Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 107:409–418
Sohn SK, Kim DH, Kim JG, Sung WJ, Baek JH, Lee NY, Won DI, Suh JS, Lee KS, Lee KB (2004) Outcome of allogeneic peripheral blood stem cell transplantation using matched sibling donors in patients with high-risk hematological diseases. Eur J Haematol 72:430–436
Acknowledgements
This study was supported by the Korean Society of Hematopoietic Stem Cell Transplantation. The authors would also like to thank the staff at each center.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kang, B.W., Moon, J.H., Chae, Y.S. et al. Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors. Ann Hematol 89, 813–820 (2010). https://doi.org/10.1007/s00277-010-0913-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-010-0913-5